Literature DB >> 457860

Tyramine kinetics and metabolism in cirrhosis.

B A Faraj, J T Fulenwider, E B Rypins, B Nordlinger, G L Ivey, R D Jansen, F M Ali, V M Camp, M Kutner, F Schmidt, D Rudman.   

Abstract

Hypertyraminemia is common in hepatic cirrhosis and correlates in severity with encephalopathy. The mechanism of cirrhotic hypertyraminemia has not been established. The alternative possibilities are increased production from tyrosine and impaired degradation by monoamine oxidase. This investigation determined the pharmacokinetics of tyramine after an intravenous bolus injections of [3H]-tyramine (180--200 muCi 12 Ci/mmol sp act) in 13 cirrhotics and 9 controls. In normals, [3H]tyramine levels initially declined rapidly (alpha-phase) followed by a slower decline (beta-phase) with an average t 1/2 of 20.8 min. Average normal metabolic clearance rate and production rate were 13.2 liters/min and 15.4 microgram/min, respectively. In cirrhotic patients, the plasma disappearance curve for [3H]tyramine was qualitatively similar to that of the control subjects with no apparent different in beta-t 1/2 (17.2 min). The hypertyraminemia of cirrhosis resulted primarily from overproduction of tyramine, as the production rate (32.0 microgram/min) in these patients was significantly greater (P less than 0.05) than in controls, whereas the metabolic clearance rate remained normal (average 12.2 liters/min). A difference in ratio of tyramine metabolic products was noted as well. Cirrhotics had a high ratio of plasma 4-hydroxyphenylethanol:4-hydroxyphenylacetic acid (60:40 vs. 30:70) as compared with normals. Although the tyramine clearance rates are similar in normals and cirrhotics, different mechanisms may be responsible for catabolism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 457860      PMCID: PMC372134          DOI: 10.1172/JCI109477

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  RAPID DETERMINATION OF PLASMA AMMONIA BY AN ION-EXCHANGE TECHNIC.

Authors:  D T FORMAN
Journal:  Clin Chem       Date:  1964-06       Impact factor: 8.327

2.  The electroencephalograph in liver disease.

Authors:  B G PARSONS-SMITH; W H SUMMERSKILL; A M DAWSON; S SHERLOCK
Journal:  Lancet       Date:  1957-11-02       Impact factor: 79.321

3.  False neurotransmitters and hepatic failure.

Authors:  J E Fischer; R J Baldessarini
Journal:  Lancet       Date:  1971-07-10       Impact factor: 79.321

4.  Plasma and urinary amino acids in Laennec's cirrhosis.

Authors:  H H Zinneman; U S Seal; R P Doe
Journal:  Am J Dig Dis       Date:  1969-02

5.  Tyrosine metabolism in cirrhosis: acquired alkaptonuria.

Authors:  B M Nordlinger; J T Fulenwider; B A Faraj; R A Bethel; D Rudman
Journal:  Surg Forum       Date:  1978

6.  Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism.

Authors:  L Rikkers; P Jenko; D Rudman; D Freides
Journal:  Gastroenterology       Date:  1978-09       Impact factor: 22.682

7.  A rapid, convenient preparative procedure for phenethylamines.

Authors:  E F Kiefer
Journal:  J Med Chem       Date:  1972-02       Impact factor: 7.446

8.  Octopamine and ammonia plasma levels in hepatic encephalopathy.

Authors:  L Capocaccia; C Cangiano; A F Attili; M Angelico; A Cascino; F Rossi Fanelli
Journal:  Clin Chim Acta       Date:  1977-02-15       Impact factor: 3.786

9.  Studies of the fate of tyramine in dogs: the effect of monoamine oxidase inhibition, portafemoral shunt and coronary artery ligation on the kinetics of tyramine.

Authors:  B A Faraj; P G Dayton; V M Camp; J P Wilson; E F Malveaux; R C Schlant
Journal:  J Pharmacol Exp Ther       Date:  1977-02       Impact factor: 4.030

10.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

View more
  3 in total

1.  Tyrosine transaminase activity in normal and cirrhotic liver.

Authors:  J M Henderson; B A Faraj; F M Ali; D Rudman
Journal:  Dig Dis Sci       Date:  1981-02       Impact factor: 3.199

2.  Effect of prolonged treatment with tyramine on glucose tolerance in streptozotocin-induced diabetic rats.

Authors:  V Visentin; P Marq; S Bour; C Subra; D Prévot; N Morin; P Valet; M C Monje; F Nepveu; C Carpéné
Journal:  J Physiol Biochem       Date:  2003-09       Impact factor: 4.158

3.  Evidence for central hypertyraminemia in hepatic encephalopathy.

Authors:  B A Faraj; V M Camp; J D Ansley; J Scott; F M Ali; E J Malveaux
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.